Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
5.06 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets: | |||||||||
| Current Assets: | |||||||||
| Cash & Cash Equivalents
| 46.329 | 69.547 | 34.273 | 15.752 | 10.686 | 9.241 | 10.271 | 8.663 | 0.527 |
| Short Term Investments
| 0 | 0 | 0 | 54.602 | 54.784 | 52.776 | 79.538 | 0 | 0 |
| Cash and Short Term Investments
| 46.329 | 69.547 | 34.273 | 70.354 | 65.47 | 62.017 | 89.809 | 8.663 | 0.527 |
| Net Receivables
| 0.077 | 4.416 | 0.487 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory
| 2.463 | 1.022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 2.31 | 2.545 | 4.355 | 3.974 | 2.18 | 2.966 | 1.343 | 0.42 | 0.017 |
| Total Current Assets
| 51.179 | 77.53 | 39.115 | 74.328 | 67.65 | 64.983 | 91.152 | 9.083 | 0.544 |
| Non-Current Assets: | |||||||||
| Property, Plant & Equipment, Net
| 2.579 | 3.615 | 5.33 | 5.502 | 4.938 | 2.201 | 0.255 | 0 | 0 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0.376 | 0.452 | 0.276 | 0.295 | 1.566 | 1.24 | 0.499 | 0 | 0 |
| Total Non-Current Assets
| 2.955 | 4.067 | 5.606 | 5.797 | 6.504 | 3.441 | 0.754 | 0 | 0 |
| Total Assets
| 54.134 | 81.597 | 44.721 | 80.125 | 74.154 | 68.424 | 91.906 | 9.083 | 0.544 |
| Liabilities & Equity: | |||||||||
| Current Liabilities: | |||||||||
| Account Payables
| 1.896 | 2.464 | 0.507 | 0.845 | 0.348 | 1.185 | 0.96 | 0.167 | 0.103 |
| Short Term Debt
| 13.605 | 0.7 | 0.297 | 41.944 | 35.513 | 0.13 | 0 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 13.511 | 13.86 | 2.655 | 3.266 | 3.114 | 2.036 | 1.517 | 0.449 | 0.316 |
| Total Current Liabilities
| 29.012 | 17.024 | 3.459 | 46.055 | 39.475 | 3.351 | 2.477 | 0.616 | 0.419 |
| Non-Current Liabilities: | |||||||||
| Long Term Debt
| 32.334 | 44.81 | 1.229 | 1.465 | 1.693 | 0.058 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 2.648 | 0 | 0 | 0 | 0 | 0 | 0 | 15.508 | 2.789 |
| Total Non-Current Liabilities
| 34.982 | 44.81 | 1.229 | 1.465 | 1.693 | 0.058 | 0 | 15.508 | 2.789 |
| Total Liabilities
| 63.994 | 61.834 | 4.688 | 47.52 | 41.168 | 3.409 | 2.477 | 16.124 | 3.208 |
| Equity: | |||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.789 |
| Common Stock
| 0.009 | 0.004 | 0.004 | 0.003 | 0.003 | 0.003 | 0.003 | 0 | 0 |
| Retained Earnings
| -307.027 | -230.448 | -163.453 | -138.966 | -103.886 | -61.192 | -33.083 | -12.435 | -2.676 |
| Accumulated Other Comprehensive Income/Loss
| 0 | 0 | 0 | -0.029 | 0.001 | 0.02 | -0.017 | 0 | 0 |
| Other Total Stockholders Equity
| 297.158 | 250.207 | 203.482 | 171.597 | 136.868 | 126.184 | 122.526 | 5.394 | -2.777 |
| Total Shareholders Equity
| -9.86 | 19.763 | 40.033 | 32.605 | 32.986 | 65.015 | 89.429 | -7.041 | -2.664 |
| Total Equity
| -9.86 | 19.763 | 40.033 | 32.605 | 32.986 | 65.015 | 89.429 | -7.041 | -2.664 |
| Total Liabilities & Shareholders Equity
| 54.134 | 81.597 | 44.721 | 80.125 | 74.154 | 68.424 | 91.906 | 9.083 | 0.544 |